CKD
61 programs · 60 companies
Programs
61
Companies
60
Trials
56
MOAs
40
EGFRiBCL-2iCD3xCD20FXIaiSOS1iJAK1iALKiIL-17iPARPiTYK2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Phase 2/3 | GIP-R | ||
| RHH-3592 | Phase 1/2 | GIP-R | ||
| Zanuderotide | Phase 1/2 | VEGF | ||
| MRK-3745 | Phase 2 | WRN | ||
| Terarelsin | Preclinical | SOS1 | ||
| Pexaosocimab | Phase 2 | PD-1 | ||
| DSN-5254 | Phase 1 | B7-H3 | ||
| ARG-3458 | Preclinical | RET | ||
| Cevifotisoran | Approved | CD47 | ||
| ION-3857 | Preclinical | Nectin-4 | ||
| Sovarasimod | Phase 1/2 | WEE1 | ||
| Polalucimab | Preclinical | PLK4 | ||
| AXS-4984 | Preclinical | JAK2 | ||
| Zoriosocimab | Approved | C5 | ||
| Peminaritide | NDA/BLA | CD20 | ||
| Bemainavolisib | NDA/BLA | PRMT5 | ||
| Zoriosocimab | Approved | SHP2 | ||
| ABS-5770 | Preclinical | FGFR | ||
| SOB-2861 | Phase 2 | RET | ||
| Fixarapivir | Preclinical | CD3 | ||
| Riluratamab | Phase 2 | GIP-R | ||
| EOR-IIT-783 | Phase 3 | HER2 | ||
| Pemiderotide | Phase 2/3 | VEGF | ||
| Tirazanubrutinib | Phase 1 | ALK | ||
| Zanurapivir | NDA/BLA | FXIa | ||
| KRO-9986 | Phase 3 | TIGIT | ||
| Oxylanthanum Carbonate | Phase 3 | GI Phosphate | ||
| PRQ-8250 | Phase 2/3 | RET | ||
| Datolucimab | Phase 1/2 | Tau | ||
| Capisotorasib | Phase 1 | CD3 | ||
| Daratenlimab | Phase 1 | EZH2 | ||
| GAL-3172 | Preclinical | CFTR | ||
| Pexaglumide | Phase 1/2 | DLL3 | ||
| Sovaosocimab | Phase 1 | PRMT5 | ||
| SHI-2889 | Phase 2 | CFTR | ||
| PRI-9923 | Phase 2/3 | BCMA | ||
| Zanufotisoran | Approved | BET | ||
| Mavuinavolisib | Phase 1 | IL-23 | ||
| Bemarapivir | Approved | CD47 | ||
| Capitinib | Phase 1 | RET | ||
| Ivorasimod | Approved | PD-1 | ||
| TRE-5650 | Phase 1/2 | AHR | ||
| HAR-6503 | Approved | CDK2 | ||
| Mavuinavolisib | NDA/BLA | SHP2 | ||
| Fixaderotide | Phase 2/3 | B7-H3 | ||
| Nirafotisoran | Preclinical | SMN2 | ||
| Sovaratamab | Phase 2/3 | FLT3 | ||
| Zorivorutinib | NDA/BLA | CGRP | ||
| Sotoglumide | Phase 2/3 | MALT1 | ||
| Bemavorutinib | Preclinical | PCSK9 | ||
| OGN-5336 | Phase 1 | IL-13 | ||
| Liralemzoparlimab | Phase 3 | PI3Kα | ||
| MVI-2801 | Preclinical | IL-17A | ||
| TES-1600 | Phase 1/2 | VEGF | ||
| Lisovorutinib | Phase 2/3 | BET | ||
| ROY-IIT-847 | Phase 1/2 | APOC3 | ||
| FRO-509 | Approved | KIF18A | ||
| WAT-3378 | Phase 2 | LAG-3 | ||
| ADA-4330 | Approved | Menin | ||
| GR-6650 | NDA/BLA | PLK4 | ||
| Pexalucimab | Phase 3 | EZH2 |
Trials (56)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07866206 | JNJ-5094 | Phase 2/3 | Terminated |
| NCT04411167 | Zanuderotide | Phase 1/2 | Terminated |
| NCT04057105 | MRK-3745 | Phase 2 | Completed |
| NCT07541605 | Pexaosocimab | Phase 2 | Completed |
| NCT07925960 | Polalucimab | Preclinical | Terminated |
| NCT08249168 | AXS-4984 | Preclinical | Terminated |
| NCT08812278 | Peminaritide | NDA/BLA | Terminated |
| NCT03318186 | Peminaritide | NDA/BLA | Terminated |
| NCT08282357 | Zoriosocimab | Approved | Terminated |
| NCT04739502 | ABS-5770 | Preclinical | Terminated |
| NCT03088559 | SOB-2861 | Phase 2 | Completed |
| NCT05802755 | SOB-2861 | Phase 2 | Completed |
| NCT04493536 | Fixarapivir | Preclinical | Completed |
| NCT06470760 | Riluratamab | Phase 2 | Recruiting |
| NCT05788434 | EOR-IIT-783 | Phase 3 | Completed |
| NCT03068775 | Pemiderotide | Phase 2/3 | Active |
| NCT07428003 | Zanurapivir | NDA/BLA | Recruiting |
| NCT08261252 | KRO-9986 | Phase 3 | Recruiting |
| NCT04629456 | Oxylanthanum Carbonate | Phase 3 | Completed |
| NCT07991010 | Oxylanthanum Carbonate | Phase 3 | Completed |